(Q40631156)

22 September 2017

title

Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk (English)

1 reference

22 September 2017

1 reference

https://api.crossref.org/works/10.1016/S0014-2999(03)02180-0

14 March 2024

author name string

Pierre Lacroix

1

1 reference

22 September 2017

Lucia Durando

3

1 reference

22 September 2017

William J. Crumb

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512100

14 March 2024

Giovanni B. Ciottoli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512100

14 March 2024

language of work or name

English

0 references

publication date

1 September 2003

1 reference

22 September 2017

5 September 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14512100

full work available at URL

14 March 2024

https://api.elsevier.com/content/article/PII:S0014299903021800?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0014-2999(03)02180-0

https://api.elsevier.com/content/article/PII:S0014299903021800?httpAccept=text/plain

14 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0014-2999(03)02180-0

European Journal of Pharmacology

14 March 2024

published in

1 reference

22 September 2017

volume

477

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

69-72

1 reference

Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902180-0

Effects of fluoroquinolones on HERG currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902180-0

Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902180-0

Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902180-0

In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902180-0

Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902180-0

In vitro antibacterial activity of a new quinolone, NM394

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902180-0

Basic safety pharmacology: the cardiovascular system

7 January 2021

9

1 reference

https://api.crossref.org/works/10.1016/S0014-2999(03)02180-0

14 March 2024

Identifiers

1 reference

22 September 2017

1 reference